Gene Therapy Cell Culture Media Market was valued at USD 142.70 million in 2018, at a CAGR of 10.9%

Introduction

Gene therapy cell culture media consists of important nutrients that provide ample energy to regulate healthy cell cycle. Moreover, it contains bovine serum, animal-derived nutrients, and growth factors like EGF, FGF, IGF, and PDGF. Growing research and development activities worldwide are prime factors for the growth of the gene therapy cell culture media. Various pharmaceutical and biotechnology companies are heavily investing in research & development of gene therapy. For instance, ‘Asklepios BioPharmaceutical Inc.’ invested USD 235 million in research & development to expand its clinical trials of gene therapy in April 2019. Similarly, ‘Pfizer’ announced an investment of USD 500 million for the construction of a gene-therapy manufacturing & research facility in Sanford, North Carolina in August 2019

Pharmaceutical & biotechnology companies are capturing the largest market share, growing at a CAGR of 10.8% in the forecast period

End user segment is divided into pharmaceutical & biotechnology companies, academic institutes, research laboratory and others. In the past few years, the market has witnessed an increase in the number of research & development activities in gene therapy for developing novel drugs for the treatment of cancer, cardiovascular diseases, metabolic diseases, lysosome storage diseases, and impaired metabolic pathways. In addition, more than 60% of the pipeline-based gene therapy molecules were tested for oncological treatments in 2018. In addition, in 2018, ‘Lonza Group Ltd’ launched a new manufacturing facility in the U.S. to increase its production capacity for viral gene and virally modified cell therapy products. ‘Brammer Bio’ also opened a new manufacturing facility for clinical and commercial gene therapy in Cambridge, MA, the U.S in 2017.

Asia Pacific is the fastest growing gene therapy market across the globe. In 2011, only 13 gene therapy trials were conducted in Asia Pacific, out of which 1 was approved by China. After 2011, out of 104 trials, more than half of gene therapies were introduced to the regional market, out of which over 36% were launched during 2014–2015. Many countries in the region are investing heavily in gene therapy research activities. For instance, Singapore government is planning to invest USD 80 million in gene therapy research & development activities, clinical trials, and manufacturing. Moreover, Indonesia, Malaysia, and Thailand have also introduced regulations to attract investors for gene therapy R&D program, which, in turn, will increase the demand for gene therapy cell culture market in the region.

Competitive Players

1. HiMedia Ltd.
2. Thermo Fischer Scientific
3. Lonza
4. Sartorius AG
5. R&D Systems Inc.(Bio-Techne)
6. GE Healthcare
7. Fujifilm Irvine Scientific

Recent Developments

Recent Developments

• On August 21^st, 2019, Pfizer invested USD 500 million for establishing new manufacturing and research facilities for gene therapy in Stanford, North Carolina.
• On January 28^th, 2020, FDA announced the Orphan Drug Regulation, which involves guidance on gene therapy manufacturing and clinical development of products, interpretation, and maintaining similarity of gene therapy products
• On November 12^th, 2019, Merck signed a license agreement with Evotec SE. The agreement provides Evotec access to Merck's foundational CRISPR intellectual property rights
• On May 6^th, 2013, Roche and BioLamina signed an R&D agreement to jointly develop new cell culture systems for various applications that highly integrates stem cell research. As per the agreement, Roche will offer R&D funding and scientific expertise to BioLamina
• On April 10^th, 2018, Lonza Group Ltd. established a new manufacturing facility in the U.S. to increase its production capacity in terms of viral gene and virally modified cell therapy products
• On June 17^th, 2015, WuXi AppTec's partnered with the University of Pennysylvania to develop viral vectors in gene therapy

Segmentation

1. By Type
   1. Stem cell media
   2. Serum-free media
   3. Specialty media
   4. Lysogeny broth
   5. Chemically defined media
   6. Custom media
2. By End-User
   1. Pharmaceutical and biotechnology companies
   2. Research laboratories
   3. Academic institutions